Cerecor has been issued a US patent covering composition claims for its centrally-acting antitussive, FP01, currently in a Phase 2b study for the treatment of chronic cough.
06:00 Aug 9, 2013
Synergy Pharmaceuticals Inc. , a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the second quarter ended June 30, 2013. Synergy is developing plecanatide for the ...
05:01 Aug 9, 2013
New market report names Quintiles as a preferred provider for Phase I studies.
05:00 Aug 9, 2013
Agilent Technologies Inc. , the Glyco-MEV laboratory at the University of Rouen, in France, and the Bioprocessing Technology Institute at the Agency for Science, Technology and Research , in Singapore, have signed a memorandum of understanding to ...
15:00 May 22, 2013
LR's International Product Innovation
00:59 Apr 8, 2013
Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor
22:11 Mar 3, 2013
Leading Internet companies, system integrators and security providers have formed the FIDO Alliance to revolutionize online authentication with an industry supported standards-based open protocol. FIDO Alliance founding member organizations Agnitio,...
21:00 Feb 11, 2013
DenTech China 2012 , approved by the Ministry of Science and Technology and organized by China International Conference Center for Science & Technology, Ninth People's Hospital of Shanghai-Jiao Tong University and Shanghai UBM ShowStar ...
19:35 Nov 19, 2012
Collaborators Will Unravel Underlying Biology of Multiple Myeloma and Advance Discovery of New Treatments
05:02 Nov 8, 2012
Tezzaron Semiconductor Completes Acquisition of SVTC's Austin Fab, Now Novati Technologies
08:53 Oct 22, 2012
Approved by the Ministry of Science and Technology and organized by the China International Conference Center for Science & Technology, the Ninth People's Hospital of Shanghai-Jiao Tong University and Shanghai UBM ShowStar Exhibition Co., Ltd, ...
19:31 Sep 24, 2012
Horizon Pharma, Inc. today announced that DUEXIS® , a proprietary single-tablet combination of ibuprofen and famotidine , is now available to U.S. physicians for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and ...
04:00 Dec 5, 2011
Patient advocacy organizations and research investigators can now take advantage of a new integrated registry and repository resource to further advance rare disease research. Blood or tissue samples donated to the NIGMS Human Genetic Cell ...
12:19 Nov 1, 2011
Signal Genetics, the parent company of Myeloma Health LLC and Respira Health LLC, a privately held predictive genetic testing company focused on oncology, announced today a new agreement under which NeoGenomics Laboratories will offer Signal ...
07:41 May 26, 2011
The International Instrument Users Association , an international organization that represents global manufacturers in the industrial automation industry, announced the second version of the Process Control Domain Security Requirements For Vendors ...
13:29 Nov 9, 2010
including New Enterprise Associates and Google Ventures.
06:02 Nov 9, 2010
Forty-five Virginia biotechnology companies were awarded more than $11 million in federal tax credits and grants today as part of the Qualifying Therapeutic Discovery Project Tax Credit Program administered by the U.S. Department of the Treasury ...
07:30 Nov 4, 2010
Global Genes Project Launches Blue Denim Inspired 'Cause Bracelets' To Be Distributed To Families Facing 7000 Different Types of Rare Diseases
03:01 Nov 1, 2010
In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m. at The Chemical Heritage Foundation, 315 ...
05:56 Aug 25, 2010
Like Vioxx, Merck's other blockbuster whose side effects emerged after it was used/tested on the public, Fosamax was launched a month early thanks to its collegial relationship with the FDA.
14:07 Apr 15, 2010